- Home
- GBLI vs AUTL Comparison
GBLI vs AUTL Comparison
Compare GBLI & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GBLI | AUTL |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 404.2M | 431.2M |
| IPO Year | 2010 | 2025 |
Fundamental Metrics
Financial Performance| Metric | GBLI | AUTL |
|---|---|---|
| Price | $29.00 | $1.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 4.8K | ★ 1.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.91% | N/A |
| EPS Growth | ★ 70.49 | 28.33 |
| EPS | ★ 1.30 | N/A |
| Revenue | ★ $441,187,000.00 | $10,120,000.00 |
| Revenue This Year | $4.18 | $669.62 |
| Revenue Next Year | $6.54 | $79.78 |
| P/E Ratio | $21.95 | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $25.88 | $1.11 |
| 52 Week High | $37.00 | $2.70 |
Technical Indicators
Market Signals| Indicator | GBLI | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 53.21 | 50.71 |
| Support Level | $28.64 | $1.27 |
| Resistance Level | $28.81 | $1.74 |
| Average True Range (ATR) | 0.53 | 0.12 |
| MACD | 0.09 | -0.01 |
| Stochastic Oscillator | 65.76 | 27.96 |
Price Performance
Historical ComparisonAbout GBLI Global Indemnity Group LLC (DE)
Global Indemnity Group LLC provides both admitted and non-admitted specialty property and casualty insurance coverages and individual policyholder coverages in the United States, as well as reinsurance world-wide. The company's two segments are: Penn-America and Non-Core Operations. The Penn-America segment offers specialty property and casualty products designed for its Wholesale Commercial, Specialty Products, InsurTech, and Assumed Reinsurance product offerings. These product lines are offered in the excess and surplus lines marketplace; and Non-Core Operations segment contains lines of business that have been de-emphasized or are no longer being written. The majority of its revenue is from the the Penn-America segment . Geographically, the majority is from California.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.